

Special Issue

Urothelial Carcinoma of the Upper Urinary Tract: What Changed?

Message from the Guest Editor

Upper tract urothelial carcinoma (UTUC) is rare, accounting for just 5–10% of all urothelial tumours. With this Special Issue on UTUC, we would like to focus on some changes and or novelties, which occurred in the last years in uncommon disease.

The tendency to opt for kidney-sparing treatment for UTUC is increasing. Nephro-ureterectomy (RNU) is no longer regarded as the only possible treatment for UTUC, especially in low-grade cancer. Adjuvant treatment is gaining popularity after any type of treatment for UTUC in order to reduce the risk of recurrence and progression.

More research and randomized clinical trials are needed to define which adjuvant systemic therapy could be applied in chronic kidney failure and in histologic variants.

Guest Editor

Prof. Dr. Lukas Lusuardi

Department of Urology & Andrology, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria

Deadline for manuscript submissions

closed (30 April 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/107098

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)